Chemotherapy causes hair loss because it targets rapidly dividing cells throughout the body, and hair follicle cells are among the fastest-dividing cells you have. Most of your scalp hair is actively growing at any given time, which makes it especially vulnerable. The same mechanism that kills cancer cells also damages the cells responsible for building each strand of hair.
How Chemotherapy Damages Hair Follicles
Hair grows from a structure called the hair matrix, a cluster of cells at the base of each follicle that divides constantly to push new hair upward. These cells are some of the most metabolically active in the human body. Chemotherapy drugs circulate through the bloodstream and attack cells that are in the process of dividing. They can’t distinguish between a cancer cell and a hair matrix cell caught mid-division.
When chemo drugs reach the hair follicle, they trigger a self-destruct process in those matrix cells. A protein called p53, which normally acts as a damage sensor inside cells, detects the chemical injury and activates a cascade that leads to cell death. This abruptly shuts down the follicle’s ability to produce hair. The hair shaft weakens, develops narrow weak points called constrictions, and eventually fractures at or near the skin’s surface. In severe cases, the entire hair bulb is affected, and the strand falls out completely rather than just breaking off.
Why Scalp Hair Falls Out First
About 85 to 90 percent of your scalp hair is in the active growth phase at any given moment, which is why scalp hair takes the hardest hit. This type of hair loss is called anagen effluvium, meaning the hair is lost while it’s still in its growth stage rather than shedding naturally at the end of its cycle.
Hair on other parts of your body grows more slowly and spends less time in the active phase. Eyelashes, eyebrows, underarm hair, and pubic hair can all be affected, but scalp hair almost always goes first. With continued treatment cycles, loss from these other areas becomes more likely as the cumulative damage builds.
Which Drugs Cause the Most Hair Loss
Not all chemotherapy drugs carry the same risk. The two classes most strongly linked to significant hair loss are taxanes and anthracyclines. More than 80 percent of patients on taxane therapy experience substantial scalp hair loss, and with cumulative treatment, eyebrows, eyelashes, and body hair can follow. Anthracycline-based regimens cause hair loss in 60 to 100 percent of patients, often beginning within one to three weeks of the first dose and progressing to near-complete loss of scalp and body hair.
Alkylating agents, another common class, cause hair loss in roughly 60 percent or more of patients with a similar pattern of gradual to rapid shedding. On the other end of the spectrum, certain drugs called antimetabolites carry a lower risk, with hair loss reported in only 10 to 50 percent of patients. Newer targeted therapies and immunotherapy drugs pose even less risk. Checkpoint inhibitors, for instance, cause hair loss in only 1 to 2 percent of patients, and when it happens, the pattern looks different from traditional chemo-related shedding.
The Typical Timeline
Hair usually starts falling out two to four weeks after your first treatment. For many people, it begins with extra hair on the pillow or in the shower drain, then accelerates. Depending on the drug and dose, shedding can be gradual or happen in clumps over just a few days. The hair shaft thins during peak drug activity, creating those structural weak points that cause strands to snap near the scalp.
After your final treatment cycle, it takes several weeks for the follicles to recover enough to start producing hair again. Most people see visible regrowth within three to six months of finishing chemotherapy. Early regrowth often appears as fine, soft fuzz before thickening over the following months.
Why Regrown Hair Looks Different
Many people notice their hair comes back curlier, finer, or a different color than it was before treatment. This is common enough that it has a nickname: “chemo curls.” The follicles were chemically damaged, and while they do recover, the process that builds the hair shaft can be temporarily altered. Residual drug effects can linger in the follicle and change how the new hair forms.
These texture and color changes are usually temporary. For most people, hair gradually returns to something closer to its original pattern over the course of a year or two, though some find the changes persist longer. In rare cases, particularly with taxane therapy, hair regrowth can be permanently thinner or sparser, especially in areas already prone to thinning.
How Scalp Cooling Works
Scalp cooling, sometimes called “cold capping,” is the most widely used method for reducing chemo-related hair loss. It works through two mechanisms: the cold constricts blood vessels in the scalp, reducing how much drug reaches the follicles, and it slows down the metabolic activity of follicle cells, making them less susceptible to the drug’s effects.
Results vary widely depending on the drug regimen, the cooling method, and how hair retention is measured. A meta-analysis found that scalp cooling reduced the overall risk of hair loss by about 62 percent. Individual studies have reported hair preservation rates anywhere from 27 percent to 82 percent. In one controlled study, about 27 percent of patients using scalp cooling had no meaningful hair loss by the end of chemotherapy, compared to zero percent in the group that didn’t use it. Scalp cooling is most effective with certain drug regimens and less effective with others, so the benefit depends heavily on your specific treatment plan.
The process involves wearing a tightly fitted cap cooled to near-freezing temperatures before, during, and after each infusion session. Some people find it uncomfortable, and sessions add time to each treatment visit. It does not work for everyone, and even when it does, some degree of thinning is common.
What Determines How Much Hair You Lose
Several factors influence the severity of hair loss beyond the specific drug. Higher doses cause more damage to follicle cells. Combination regimens that pair multiple drugs together tend to cause more hair loss than single-agent treatments. The number of treatment cycles matters too, since each round delivers another wave of damage before follicles can recover.
Individual biology plays a role as well. People vary in how their follicle cells process and respond to chemotherapy drugs. Some patients on the same regimen lose nearly all their hair while others retain a fair amount. Age, nutritional status, and pre-existing hair conditions can also influence the outcome, though the drug regimen remains the strongest predictor.